Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies.

Kroth H, Oden F, Molette J, Schieferstein H, Capotosti F, Mueller A, Berndt M, Schmitt-Willich H, Darmency V, Gabellieri E, Boudou C, Juergens T, Varisco Y, Vokali E, Hickman DT, Tamagnan G, Pfeifer A, Dinkelborg L, Muhs A, Stephens A.

Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2178-2189. doi: 10.1007/s00259-019-04397-2. Epub 2019 Jul 1.

2.

The characterization of 18F-hGTS13 for molecular imaging of xC- transporter activity with positron emission tomography.

Beinat C, Gowrishankar G, Shen B, Alam IS, Robinson E, Haywood T, Patel CB, Azevedo EC, Castillo J, Ilovich O, Koglin N, Schmitt-Willich H, Berndt M, Mueller A, Zerna M, Srinivasan A, Gambhir SS.

J Nucl Med. 2019 Jun 6. pii: jnumed.119.225870. doi: 10.2967/jnumed.119.225870. [Epub ahead of print]

PMID:
31171595
3.

Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies.

Mittra ES, Koglin N, Mosci C, Kumar M, Hoehne A, Keu KV, Iagaru AH, Mueller A, Berndt M, Bullich S, Friebe M, Schmitt-Willich H, Gekeler V, Fels LM, Bacher-Stier C, Moon DH, Chin FT, Stephens AW, Dinkelborg LM, Gambhir SS.

PLoS One. 2016 Feb 18;11(2):e0148628. doi: 10.1371/journal.pone.0148628. eCollection 2016.

4.

Preclinical characterization of a novel class of 18F-labeled PET tracers for amyloid-β.

Brockschnieder D, Schmitt-Willich H, Heinrich T, Varrone A, Gulyás B, Toth M, Andersson J, Boemer U, Krause S, Friebe M, Dinkelborg L, Halldin C, Dyrks T.

J Nucl Med. 2012 Nov;53(11):1794-801. doi: 10.2967/jnumed.112.104810. Epub 2012 Sep 24.

5.

Specific PET imaging of xC- transporter activity using a ¹⁸F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism.

Koglin N, Mueller A, Berndt M, Schmitt-Willich H, Toschi L, Stephens AW, Gekeler V, Friebe M, Dinkelborg LM.

Clin Cancer Res. 2011 Sep 15;17(18):6000-11. doi: 10.1158/1078-0432.CCR-11-0687. Epub 2011 Jul 12.

6.

High relaxivity magnetic resonance imaging contrast agents. Part 1. Impact of single donor atom substitution on relaxivity of serum albumin-bound gadolinium complexes.

Dumas S, Jacques V, Sun WC, Troughton JS, Welch JT, Chasse JM, Schmitt-Willich H, Caravan P.

Invest Radiol. 2010 Oct;45(10):600-12. doi: 10.1097/RLI.0b013e3181ee5a9e.

7.

Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.

Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, Walter J, Weinmann HJ, Pietsch H.

Eur Radiol. 2008 Oct;18(10):2164-73. doi: 10.1007/s00330-008-0977-y. Epub 2008 Jun 11.

PMID:
18545998
8.

Stability of linear and macrocyclic gadolinium based contrast agents.

Schmitt-Willich H.

Br J Radiol. 2007 Jul;80(955):581-2; author reply 584-5. No abstract available.

PMID:
17704318
9.

In vivo evaluation of gadolinium hydroxypyridonate chelates: initial experience as contrast media in magnetic resonance imaging.

Thompson MK, Misselwitz B, Tso LS, Doble DM, Schmitt-Willich H, Raymond KN.

J Med Chem. 2005 Jun 2;48(11):3874-7.

PMID:
15916439
10.

NMR and chiroptical examination of the diastereoisomers of (S)-Eu-EOB-DTPA.

Thompson NC, Parker D, Schmitt-Willich H, Sulzle D, Muller G, Riehl JP.

Dalton Trans. 2004 Jun 21;(12):1892-5. Epub 2004 May 19.

PMID:
15381997
11.

Tissue-specific MR contrast agents.

Weinmann HJ, Ebert W, Misselwitz B, Schmitt-Willich H.

Eur J Radiol. 2003 Apr;46(1):33-44. Review.

PMID:
12648800
12.

Early distribution dynamics of polymeric magnetic resonance imaging contrast agents in rats.

Weinmann HJ, Bauer H, Griesinger C, Ebert W, Misselwitz B, Mühler A, Schmitt-Willich H.

Acad Radiol. 2002 Aug;9 Suppl 2:S412-6. No abstract available.

PMID:
12188293
13.

Comparative studies on the efficacy of MRI contrast agents in MRA.

Weinmann HJ, Bauer H, Ebert W, Frenzel T, Radüchel B, Platzek J, Schmitt-Willich H.

Acad Radiol. 2002 May;9 Suppl 1:S135-6. No abstract available.

PMID:
12019849
14.

The impact of rigidity and water exchange on the relaxivity of a dendritic MRI contrast agent.

Nicolle GM, Tóth E, Schmitt-Willich H, Radüchel B, Merbach AE.

Chemistry. 2002 Mar 1;8(5):1040-8.

PMID:
11891890
15.

Interstitial magnetic resonance lymphography using a polymeric t1 contrast agent: initial experience with Gadomer-17.

Misselwitz B, Schmitt-Willich H, Michaelis M, Oellinger JJ.

Invest Radiol. 2002 Mar;37(3):146-51.

PMID:
11882794
16.

Synthesis and Physicochemical Characterization of a New Gadolinium Chelate: The Liver-Specific Magnetic Resonance Imaging Contrast Agent Gd-EOB-DTPA.

Schmitt-Willich H, Brehm M, Ewers CL, Michl G, Müller-Fahrnow A, Petrov O, Platzek J, Radüchel B, Sülzle D.

Inorg Chem. 1999 Mar 22;38(6):1134-1144.

PMID:
11670895
17.

Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent.

Misselwitz B, Schmitt-Willich H, Ebert W, Frenzel T, Weinmann HJ.

MAGMA. 2001 May;12(2-3):128-34.

PMID:
11390268
18.

Effect of varying the molecular weight of the MR contrast agent Gd-DTPA-polylysine on blood pharmacokinetics and enhancement patterns.

Vexler VS, Clément O, Schmitt-Willich H, Brasch RC.

J Magn Reson Imaging. 1994 May-Jun;4(3):381-8.

PMID:
8061437
19.

The demonstration of human tumors on nude mice using gadolinium-labelled monoclonal antibodies for magnetic resonance imaging.

Göhr-Rosenthal S, Schmitt-Willich H, Ebert W, Conrad J.

Invest Radiol. 1993 Sep;28(9):789-95.

PMID:
8225882
20.

Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat.

Schuhmann-Giampieri G, Schmitt-Willich H, Frenzel T, Schitt-Willich H [corrected to Schmitt-Willich H].

J Pharm Sci. 1993 Aug;82(8):799-803. Erratum in: J Pharm Sci 1993 Dec;82(12):1300.

PMID:
8377117
21.

Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging.

Schuhmann-Giampieri G, Frenzel T, Schmitt-Willich H.

Arzneimittelforschung. 1993 Aug;43(8):927-31.

PMID:
8216456
22.

Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system.

Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U.

Radiology. 1992 Apr;183(1):59-64.

PMID:
1549695
23.

A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI.

Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Gries H.

Magn Reson Med. 1991 Dec;22(2):233-7; discussion 242.

PMID:
1812351
24.

In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast agent for magnetic resonance imaging.

Schuhmann-Giampieri G, Schmitt-Willich H, Frenzel T, Press WR, Weinmann HJ.

Invest Radiol. 1991 Nov;26(11):969-74.

PMID:
1743920

Supplemental Content

Loading ...
Support Center